These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38307775)

  • 1. Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy.
    Fournier M; Mortier L; Dereure O; Dalac S; Oriano B; Dalle S; Lebbé C
    Eur J Cancer; 2024 Mar; 200():113562. PubMed ID: 38307775
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter re: Hyperprogression in advanced melanoma is not restricted to immunotherapy.
    Yang F; Xu N
    Eur J Cancer; 2024 Mar; 199():113507. PubMed ID: 38219642
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
    Schuiveling M; Tonk EHJ; Verheijden RJ; Suijkerbuijk KPM
    Cancer Immunol Immunother; 2021 May; 70(5):1491-1496. PubMed ID: 32929554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprogression after nivolumab for melanoma: A case report.
    Yilmaz M; Akovali B
    J Oncol Pharm Pract; 2020 Jan; 26(1):244-251. PubMed ID: 31068087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.
    Frelaut M; du Rusquec P; de Moura A; Le Tourneau C; Borcoman E
    BioDrugs; 2020 Aug; 34(4):463-476. PubMed ID: 32394415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.
    Theivanthiran B; Yarla N; Haykal T; Nguyen YV; Cao L; Ferreira M; Holtzhausen A; Al-Rohil R; Salama AKS; Beasley GM; Plebanek MP; DeVito NC; Hanks BA
    Sci Transl Med; 2022 Nov; 14(672):eabq7019. PubMed ID: 36417489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprogression in advanced melanoma is not restricted to immunotherapy.
    Fournier M; Mortier L; Dereure O; Dalac S; Oriano B; Dalle S; Lebbé C
    Eur J Cancer; 2023 Nov; 193():113289. PubMed ID: 37690179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogression under Immunotherapy.
    Frelaut M; Le Tourneau C; Borcoman E
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic Evolution of Melanocytes Associated With Rapid Clinical Progression of Melanoma: Clinicopathologic Presentation of Hyperprogressive Disease in a Patient Treated With Immunotherapy.
    Almanza J; Dobry A; Ejadi S; Jakowatz J; Lee B
    Am J Dermatopathol; 2022 Dec; 44(12):921-924. PubMed ID: 36395449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel patterns of response under immunotherapy.
    Borcoman E; Kanjanapan Y; Champiat S; Kato S; Servois V; Kurzrock R; Goel S; Bedard P; Le Tourneau C
    Ann Oncol; 2019 Mar; 30(3):385-396. PubMed ID: 30657859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience.
    Yilmaz M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1106-1111. PubMed ID: 32799776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprogression after immunotherapy.
    Abbas W; Rao RR; Popli S
    South Asian J Cancer; 2019; 8(4):244-246. PubMed ID: 31807489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogression as a distinct outcome after immunotherapy.
    Fuentes-Antrás J; Provencio M; Díaz-Rubio E
    Cancer Treat Rev; 2018 Nov; 70():16-21. PubMed ID: 30053725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma.
    Wang J; Wang X; Yang X; Zhao H; Huo L
    Clin Nucl Med; 2020 Jan; 45(1):92-93. PubMed ID: 31789917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
    Zhou L; Zhang M; Li R; Xue J; Lu Y
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3269-3279. PubMed ID: 32857178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.
    Ji Z; Peng Z; Gong J; Zhang X; Li J; Lu M; Lu Z; Shen L
    BMC Cancer; 2019 Jul; 19(1):705. PubMed ID: 31315610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma.
    Caner B; Ertas H; Ocak B; Cubukcu E
    J Oncol Pharm Pract; 2022 Oct; 28(7):1645-1649. PubMed ID: 35188841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
    Zhou L; Yang Y; Si L; Chi Z; Sheng X; Lian B; Wang X; Tang B; Mao L; Yan X; Li S; Bai X; Guo J; Cui C
    Melanoma Res; 2022 Jun; 32(3):142-149. PubMed ID: 35190519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and overall survival among anti-PD-1-exposed advanced melanoma patients with evidence of disease progression.
    Pinto CA; Liu X; Li X; Scherrer E; Kalabis M
    Immunotherapy; 2022 Mar; 14(4):201-214. PubMed ID: 34870445
    [No Abstract]   [Full Text] [Related]  

  • 20. Research progress in advanced melanoma.
    Luo C; Shen J
    Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.